
Name
RICE
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for RICE
Name
Alternate Names
Dom-Etoposide
Epipodophyllotoxin derivative
Epipodophyllotoxin ethylidene gluco-pyranoside
Eposine
Ethylidene-Lignan P
Etopophos
Podophyllotoxin derivative
Vepesid
VP 16-213
VP-16
VP-16213
Toposar
Abbreviations
EPEG
VP-16
VP-16-213
Category
Chemotherapy
Subcategory
Epipodophyllotoxin, topoisomerase II inhibitor
Plant alkaloid
NSC Number
141540
Primary Site
Histology
None
Remarks
Coding
This drug should be coded
Name
Alternate Names
Anti-CD20 monoclonal antibodies
C2B8 monoclonal antibody
IDEC-C2B8
MabThera
Monoclonal antibody IDEC-C2B8
Rituxan
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Cytostatic monoclonal antibody
NSC Number
687451
Primary Site
Leukemia
NHL
Histology
None
Remarks
December 2, 2021 The FDA approved rituximab (Rituxan, Genentech, Inc.) in combination with chemotherapy for pediatric patients (≥6 months to <18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL).
JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Rituximab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Rituximab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding as chemotherapy.
FDA approved 2/2006 for treatment of diffuse large B-cell, CD-20 positive non-Hodgkin lymphoma.
FDA approved 9/2006 for non-Hodgkin's B-cell lymphoma. Also used to treat autoimmune disorders, hemolytic anemia and ITP.
FDA approved 2/2010 for use in combination with cyclophosphamide and fludarabine in treatment of CLL.
FDA approved for maintenance therapy for previously untreated follicular CD-20 positive B-cell non-Hodgkin lymphoma who achieved response to rituximab in combination with chemotherapy.
June 22, 2017 FDA granted regular approval to the combination of rituximab and hyaluronidase human (RITUXAN HYCELA) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.
.
JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Rituximab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Rituximab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding as chemotherapy.
FDA approved 2/2006 for treatment of diffuse large B-cell, CD-20 positive non-Hodgkin lymphoma.
FDA approved 9/2006 for non-Hodgkin's B-cell lymphoma. Also used to treat autoimmune disorders, hemolytic anemia and ITP.
FDA approved 2/2010 for use in combination with cyclophosphamide and fludarabine in treatment of CLL.
FDA approved for maintenance therapy for previously untreated follicular CD-20 positive B-cell non-Hodgkin lymphoma who achieved response to rituximab in combination with chemotherapy.
June 22, 2017 FDA granted regular approval to the combination of rituximab and hyaluronidase human (RITUXAN HYCELA) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.
.
Coding
This drug should be coded
Name
Alternate Names
A-4942
Asta Z-4942
Cyfos#
Holoxan 1000
Ifex
Ifosfamid
Ifoxan
Iphosphamid
Iphosphamide
Iso-endoxan
Isofosfamide
Isophos-phamide
Isophosphamide
Mitoxana
MJF 9325
MJF-9325
Naxamide#
Z4942
Abbreviations
IFX
IPP
Category
Chemotherapy
Subcategory
Alkylating agent
NSC Number
109724
Primary Site
Bladder
Cervical cancer
Ewing sarcoma
Head and Neck
Hodgkin lymphoma
Non-Hodgkin lymphoma
Soft tissue sarcoma, osteogenic sarcoma
Testicular cancer
Histology
None
Remarks
Antineoplastic with alkylating activity. FDA approved.
Coding
This drug should be coded
Name
Alternate Names
JM 8
JM-8
JM8
Paraplatin
Abbreviations
CBDCA
Category
Chemotherapy
Subcategory
Alkylating agent
Platinum analog
NSC Number
241240
Primary Site
All cancers
Histology
None
Remarks
A platinum-salt alkylating agent.
Coding
This drug should be coded
